Pyxis Oncology, Inc.
For the period ended Dec 31, 2025. Filed Mar 23, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 23, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Trading arrangement
During the quarter ended December 31, 2025, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act)adoptedor terminatedany “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K for the purchase or sale of our securities, except as set forth below:
| Name and Title | Type of Plan | Adoption or Termination Date | Plan Start Date | Plan End Date | Aggregate Number of Securities to be Sold | Description of Trading Arrangement |
|---|---|---|---|---|---|---|
| Lara Sullivan, M.D., Former President, Chief Executive Officer and Chief Medical Officer and Current Director | Rule 10b5-1 trading arrangement | Adopted on December 22, 2025 | December 22, 2025 | March 31, 2027 | 411,845 | Sales of shares intended to satisfy the affirmative defense of Rule 10b5–1(c) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.